ADVFN
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,296.79
      -0.01%
      US Tech 100
      22,458.00
      -0.06%
      Dow Jones
      44,342.19
      -0.32%
      Brent Oil
      68.685
      0.00%
      Bitcoin
      117,937.85
      -0.02%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. INmune Bio Inc (INMB) Quote

      INmune Bio Inc

      INmune Bio Inc (INMB)

      NASDAQ
      2.42
      0.18
      (8.04%)
      Closed July 19 4:00PM
      Sign in for streaming prices
      2.3598
      -0.0602
      (-2.49%)
      After Hours: 7:54PM
      Sign in for streaming prices

      INmune Bio Inc (INMB) Quote

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      2.3598
      ( 5.35% )
      Bid
      2.33
      Ask
      2.40
      Volume
      1,976,482
      2.2401 Day's Range 2.48
      1.89 52 Week Range 11.64
      Market Cap
      54.772M
      Previous Close
      2.24
      Open
      2.26
      Last Trade
      63
      @
      2.36
      Last Trade Time
      Financial Volume
      $ 4,617,759
      VWAP
      2.3364
      Average Volume (3m)
      2,718,772
      Shares Outstanding
      23,210,377
      Dividend Yield
      -
      PE Ratio
      -1.34
      Earnings Per Share (EPS)
      -1.81
      Revenue
      14k
      Net Profit
      -42.08M

      About INmune Bio Inc

      INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others. INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Headquarters
      Carson City, Nevada, USA
      Founded
      -
      INmune Bio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker INMB. The last closing price for INmune Bio was $2.24. Over the last year, INmune Bio shares have traded in a share price range of $ 1.89 to $ 11.64.

      INmune Bio currently has 23,210,377 shares outstanding. The market capitalization of INmune Bio is $51.99 million. INmune Bio has a price to earnings ratio (PE ratio) of -1.34.

      Ask ADVFN Intelligence (AI)

      INmune Bio (INMB) Options Flow Summary

      INMB Options Flow

      Overall Flow

      Bearish

      Net Premium

      -1M

      Calls / Puts

      0.00%

      Buys / Sells

      750.00%

      OTM / ITM

      0.00%

      Sweeps Ratio

      0.00%

      INMB Latest News

      More News

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 30 2025
      INMB (8.04%)

      Form 424B5 - Prospectus [Rule 424(b)(5)]
      Edgar (US Regulatory)
      June 30 2025
      INMB (8.04%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 30 2025
      INMB (8.04%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 26 2025
      INMB (8.04%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 10 2025
      INMB (8.04%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.13986.29729729732.222.462.0416842602.23569507CS
      4-4.9402-67.67397260277.311.641.8973124313.89505608CS
      12-5.6002-70.35427135687.9611.641.8927187724.26996815CS
      26-4.2052-64.05483625296.56511.641.8914480124.76801146CS
      52-6.6602-73.83813747239.0211.641.898337184.91990835CS
      156-8.0002-77.22200772210.3614.741.893243625.55912682CS
      260-9.0502-79.318141980711.4130.371.892973908.9368899CS

      INMB - Frequently Asked Questions (FAQ)

      What is the current INmune Bio share price?
      The current share price of INmune Bio is $ 2.3598
      How many INmune Bio shares are in issue?
      INmune Bio has 23,210,377 shares in issue
      What is the market cap of INmune Bio?
      The market capitalisation of INmune Bio is USD 51.99M
      What is the 1 year trading range for INmune Bio share price?
      INmune Bio has traded in the range of $ 1.89 to $ 11.64 during the past year
      What is the PE ratio of INmune Bio?
      The price to earnings ratio of INmune Bio is -1.34
      What is the cash to sales ratio of INmune Bio?
      The cash to sales ratio of INmune Bio is 4.05k
      What is the reporting currency for INmune Bio?
      INmune Bio reports financial results in USD
      What is the latest annual turnover for INmune Bio?
      The latest annual turnover of INmune Bio is USD 14k
      What is the latest annual profit for INmune Bio?
      The latest annual profit of INmune Bio is USD -42.08M
      What is the registered address of INmune Bio?
      The registered address for INmune Bio is 701 S CARSON ST, STE 200, CARSON CITY, NEVADA, 89701
      Which industry sector does INmune Bio operate in?
      INmune Bio operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      NEXMNexMetals Mining Corporation
      $ 6.50
      (173.11%)
      		103.24k
      TELOTelomir Pharmaceuticals Inc
      $ 2.295
      (89.67%)
      		135.81M
      IXHLIncannex Healthcare Ltd
      $ 0.6001
      (62.15%)
      		491.07M
      CYCCCyclacel Pharmaceuticals Inc
      $ 13.07
      (58.81%)
      		22.37M
      BZAIBlaize Holdings Inc
      $ 4.80
      (58.42%)
      		73.13M
      PTNMPitanium Ltd
      $ 2.18
      (-67.02%)
      		4.62M
      YHCLQR House Inc
      $ 2.38
      (-63.77%)
      		9.93M
      KMRKK Tech Solultions Company Ltd
      $ 2.45
      (-44.94%)
      		12.06M
      SRPTSarepta Therapeutics Inc New
      $ 14.07
      (-35.96%)
      		78.44M
      CLSDClearside Biomedical Inc
      $ 0.4076
      (-32.27%)
      		3.66M
      OPENOpendoor Technologies Inc
      $ 2.25
      (36.36%)
      		589.71M
      IXHLIncannex Healthcare Ltd
      $ 0.6001
      (62.15%)
      		491.41M
      BTOGBit Origin Ltd
      $ 0.7675
      (21.63%)
      		362.58M
      LCIDLucid Group Inc
      $ 3.035
      (-2.72%)
      		294.46M
      NVDANVIDIA Corporation
      $ 172.41
      (-0.34%)
      		146.48M

      INMB Discussion

      View Posts
      jondoeuk jondoeuk 3 weeks ago
      The trial missed its primary endpoint. The trial also missed its secondary endpoints. I doubt they will find a partner to advance it.
      👍️0
      tredenwater2 tredenwater2 3 weeks ago
      Perhaps INMB wojld have benefitted from using the FDA’s open label adaptive ph 2 cross over trial like Anavex did. We are clearly on a firm foundation of efficacy because if the ph 2a as we near approval in the EU.

      On a financing note, yes I also highly appreciate Dr. Missling’s clear savvy moves to minimally allow dilution to Anavex shareholders on the way to approval…..inhouse!

      Management of INMB should be ashamed for securing a financing deal ahead of releasing bad news. Did the funding source know the data and shorted against the box? Smells very bad!
      👍️ 2
      tschussmann1 tschussmann1 3 weeks ago
      Every Alzheimer's trial fail makes me appreciate AVXL that much more...
      👍️ 2
      tschussmann1 tschussmann1 3 weeks ago
      Yes indeed! Fortunately it was a small stake...not much effect on the portfolio.
      👍️0
      retireat40 retireat40 3 weeks ago
      Looks like a terrible decision 
      👍️0
      tschussmann1 tschussmann1 3 weeks ago
      The low 5's after the 20% share increase priced at 6.30 provided a nice entry point...and not long to wait to see it it was a good decision.
      👍️ 2
      murocman murocman 3 weeks ago
      Happens all the time.  Not a surprise.
      👍️0
      retireat40 retireat40 3 weeks ago
      $5's
      👍️0
      retireat40 retireat40 3 weeks ago
      Then they dropped an offering at $6.30. What a shit move. 
      👍️0
      rbl100 rbl100 3 weeks ago
      OFFERING - @ $6.30 per share.....
      👍️0
      tw0122 tw0122 3 weeks ago
      $13s 
      👍️0
      GhosTraderX GhosTraderX 3 weeks ago
      INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
      https://ih.advfn.com/stock-market/NASDAQ/inmune-bio-INMB/stock-news/96320079/inmune-bio-inc-to-announce-top-line-results-from
      GhosT
      👍️ 4
      jondoeuk jondoeuk 1 month ago
      An update https://www.globenewswire.com/news-release/2025/06/02/3091859/0/en/Syncromune-Inc-Presents-Positive-Results-from-SYNC-T-Therapy-SV-102-Phase-1-Metastatic-Prostate-Cancer-Trial-at-ASCO-2025.html

      https://www.globenewswire.com/news-release/2025/05/30/3091053/0/en/Syncromune-Announces-First-Patient-Dosed-in-LEGION-100-Phase-2a-Trial-of-SYNC-T-Therapy-SV-102-for-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer.html
      👍️0
      jondoeuk jondoeuk 4 months ago
      Apples to oranges, but this is the kind of data you want to see https://syncromune.com/wp-content/uploads/2024/04/SYNC-T-AACR-Website.pdf
      👍️0
      jondoeuk jondoeuk 4 months ago
      So no scans, waterfall or swimmer plots! Doesn't look like there is any single-agent activity https://archive.fast-edgar.com/20250304/AD29K22CLM22K282222G22Y2M9BIZ2224272/ea023314201ex99-1_inmune.htm

      Drugs with no single-agent activity rarely, if ever improve outcomes in randomised and controlled trials when used alone or in combination.
      👍️0
      MartinLutherKing MartinLutherKing 7 months ago
      ELAB Partnership
      👍️0
      Monksdream Monksdream 7 months ago
      INMB under $5
      👍️0
      Monksdream Monksdream 9 months ago
      INMB new 52 week low
      👍️0
      tw0122 tw0122 9 months ago
      Study Demonstrate XPro converts microglia from a demyelinating cell to a remyelinating cell.Multi-year study published has implications for many CNS diseases including Alzheimer's.
      👍️0
      tw0122 tw0122 9 months ago
      INMB 5.27 something brewing over here in some
      👍️0
      Monksdream Monksdream 10 months ago
      INMB new 52 week low
      👍️0
      Monksdream Monksdream 1 year ago
      INMB under $10
      👍️0
      jondoeuk jondoeuk 1 year ago
      ''The third patient for the INKmune™ AML program in UK and EU has been enrolled and subsequent to their completion of follow-up, the company will wind down the AML program to focus resources on the prostate-cancer program and other solid tumors.'' https://www.globenewswire.com/news-release/2024/03/28/2854450/0/en/INmune-Bio-Inc-Announces-Year-End-2023-Results-and-Provides-a-Q4-Business-Update.html

      Good luck to them in solid tumours!
      👍️0
      Monksdream Monksdream 2 years ago
      INMB indeed it did
      👍️0
      DollarDan DollarDan 2 years ago
      Starting to move up!
      👍️0
      jondoeuk jondoeuk 2 years ago
      Did the trial in ovarian ever start?
      👍️0
      derkampfer derkampfer 2 years ago
      Don't need to convince us. We are fully invested and believers in both the INKmune NK cell therapy for certain cancers as well as XPro for AD and possibly others neuro inflammation sensitive diseases, including Parkinson’s.

      Two robust programs and each have multi-billion value potential based on TAM

      Exciting times.

      GLTA longs
      👍️0
      jondoeuk jondoeuk 2 years ago
      Sure, it is early days in patients, but the data has yet to be https://ashpublications.org/blood/article/140/Supplement%201/4590/492304/In-Vivo-Generation-of-Memory-like-NK-Cells-for-the

      Keep in mind that the ORR (focusing on R/R AML) is ~30-35% across multiple trials using adoptive transfer of non-engineered NK cells.
      👍️0
      dennisdave dennisdave 3 years ago
      blocked
      👍️0
      conix conix 3 years ago
      INMB chart....finally a reversal?

      👍️0
      conix conix 4 years ago
      INMB Chart

      👍️0
      derkampfer derkampfer 4 years ago
      XPro news also impressive. Data very.

      “The data from this Phase I trial show that XPro decreases biomarkers of neuroinflammation and nerve cell death while improving biomarkers of neurorepair in patients with AD,” stated RJ Tesi, M.D., CEO of INmune Bio
      👍️0
      derkampfer derkampfer 4 years ago
      INKmune news was impressive. Albeit one patient dosed additional eight (8) in line. No toxicity. Ovarian cancer on deck.

      https://finance.yahoo.com/news/inmune-bio-inc-announces-biomarker-200000970.html
      👍️0
      spartex spartex 4 years ago
      Almost, $13 to $10 is a downward slope. but maybe over time things will be reversed??
      👍️0
      spartex spartex 4 years ago
      Booooooom? More like, BurP! LOL. Still researching INMB
      👍️0
      derkampfer derkampfer 4 years ago
      New run began today. Deeper dive Alzheimer’s drug they’re developing is phenomenal. Early studies some patients seeing reversed effects.

      Unbelievable.
      👍️0
      Fress Fress 4 years ago
      $INMB just ran from $2.00 to 30.00 congrats to the longs. what a beast of a stock.



      *INmune Bio shares are trading higher after the company announced results for its Phase 1B study of XPro1595. The results show a decrease in biomarkers of neuroinflammation across multiple measures and assays, including cerebrospinal fluid and MRI.



      $PDSB CD8+ (killer) T-cells. T cell platform is next.


      $INMB
      👍️0
      john sezso john sezso 5 years ago
      I need a bigger rake to scoop up all this cash trade....
      👍️0
      john sezso john sezso 5 years ago
      Still crickets here....
      👍️0
      john sezso john sezso 5 years ago
      Good enough for Harry Reid it's good enough for me. I'm in for the 50's
      👍️0
      byrdiesoccer byrdiesoccer 5 years ago
      They are speaking with Roth Capital right now
      👍️0
      akamaii akamaii 5 years ago
      Shorts bring this to 8 I wanna buy
      👍️0
      l2 hunter l2 hunter 5 years ago
      INMB CHART >>>> going in position before test $25 next days again. after $25 blue skies... $13-$15 range a gift imho think will run big next days

      👍️0
      starkd748 starkd748 5 years ago
      Wow that public offering is peanuts ...Kaboom here tomorrow
      👍️0
      l2 hunter l2 hunter 5 years ago
      INMB ready to test $24 high from last week next days.. strong technical setting now.
      👍️0
      l2 hunter l2 hunter 5 years ago
      INMB NEWS OUT!!!!!!!!! BOOOOOOOOOOOOOOOOOOOOMMMMMMMMMMMMMMMMMMMMMMMM
      👍️0
      l2 hunter l2 hunter 5 years ago
      INMB CHART >>> Strong setting for next big wave above $20 next week if News update drop imho >>>>>

      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $INMB Video Chart 07-14-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      dinogreeves dinogreeves 5 years ago
      Looks like a strong close finally.
      👍️0
      $treet $inatra $treet $inatra 5 years ago
      INMB monster pop https://finance.yahoo.com/news/inmune-bio-inc-announces-interim-201600548.html
      👍️0

      Your Recent History

      NASDAQ
      INMB
      INmune Bio
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads